Biotech Showcase™ 2017: ProNAI defects from oligos to DDR as Sierra Oncology

January 26, 2017
Sierra Oncology president and CEO Dr. Nick Glover tells Mike Ward, Informa Pharma Intelligence insight global director of content, how the company is rebranding itself from its former incarnation ProNAI Therapeutics, armed with two in-licensed assets focused on DNA damage repair (DDR) and USD 100 million in the bank.
Previous Article
Breaking news:  Creating a healthcare futures market
Breaking news: Creating a healthcare futures market

Dennis Purcell, founder and senior advisor of Aisling Capital LLC, and co-founder of Poliwogg, is creating ...

Next Video
Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry
Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry

With the Chinese market growing at 10–15% a year, it is poised to be world’s largest by 2026. Tony Chu, co-...